Activated Rb Drives Estrogen Genes in HR+ Breast Cancer, Limiting CDK4/6 Benefit in 44 Patients
Updated
Updated · Oncodaily · Aug 14
Activated Rb Drives Estrogen Genes in HR+ Breast Cancer, Limiting CDK4/6 Benefit in 44 Patients
3 articles · Updated · Oncodaily · Aug 14
Summary
Researchers found CDK4/6 inhibitors activate hypophosphorylated Rb, which not only represses cell-cycle genes but also switches on estrogen-responsive genes that can support tumor growth in HR-positive breast cancer.
15,218 Rb chromatin “up peaks” appeared in one breast-cancer cell line after abemaciclib, with Rb relocating into ER-rich enhancer and promoter hubs; the effect depended on Rb and was partly mediated through KDM5A.
44 paired tumors from the POP trial showed palbociclib suppressed E2F targets yet induced estrogen-response gene sets, matching results in cell lines and patient-derived xenografts.
Fulvestrant blunted that Rb-driven estrogen program and deepened growth suppression, helping explain why endocrine therapy synergizes with CDK4/6 inhibitors.
ESR1-mutant, endocrine-resistant models kept the Rb-driven program active under estrogen deprivation, suggesting selective ER degraders may better restore full cell-cycle control.
How might the paradoxical dual role of the Rb protein reshape our approach to overcoming endocrine resistance in breast cancer?
Could the very drugs designed to halt breast cancer secretly be flipping the genetic switch to fuel its survival?
Rb’s Paradox in Breast Cancer: Mechanisms of CDK4/6 Inhibitor Resistance, Real-Time Genomic Monitoring, and Next-Generation Therapeutic Strategies
Overview
This report highlights a major breakthrough in breast cancer research, revealing that activating the Rb protein with CDK4/6 inhibitors not only stops cell division but also unexpectedly turns on estrogen-responsive genes, helping cancer cells survive. Combining CDK4/6 inhibitors with endocrine therapies can block this survival pathway, leading to better treatment outcomes. However, tumors can develop resistance by losing the RB1 gene, activating alternative pathways like Cyclin E-CDK2 or PI3K/AKT/mTOR, or creating an immunosuppressive environment. New strategies, such as using CDK2 inhibitors, targeting the tumor microenvironment, and integrating lifestyle changes, are being explored to overcome resistance and personalize therapy.